Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study

This publication has 40 references indexed in Scilit:

• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
  The Lancet, 2006
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2005
• Plaque regression—A new target for antiatherosclerotic therapy
  American Heart Journal, 2005
• Lessons from human mutations in PPARγ
  International Journal of Obesity, 2005
• Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome
  Circulation, 2005
• Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome
  JAMA, 2004
• Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease
  Journal of the American College of Cardiology, 2004
• Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 Diabetes
  Circulation, 2003
• The metabolic syndrome, diabetes, and subclinicalatherosclerosis assessed by coronary calcium
  Journal of the American College of Cardiology, 2003